CONCLUSIONS The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect  compared with statin monotherapy .
AIMS Statins are known to influence the status of adipokines , which play a key role in the pathophysiology of cardiometabolic diseases .
As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear , the aim of the present study was to investigate this through a meta- analysis of controlled trials .
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia
Lipid-lowering therapy is associated with  reduced cardiovascular risk .  The aim of the present study was to investigate whether lipid-lowering therapy might be associated with changes in the concentrations of metabolically important hormone concentrations . We performed a r and omised cross-over open-label trial with atorvastatin ( 10 mg/day ) and fenofibrate ( 200 mg/day ) , each for 6 weeks separated by a 6-week washout period in 13 patients ( 5 men , 8 women , age 60.0±6.8 years , body mass index 30.0±3.0 kg/m2 ) with type 2 diabetes mellitus and mixed hyperlipoproteinaemia .  Plasma ghrelin ( RIA , Phoenix Pharmaceuticals , Mountain View , CA , USA ) , adiponectin ( ELISA , Biovendor , Heidelberg , Germany ) as well as resistin ( ELISA , Linco Research , St. Charles , MO , USA ) concentrations were measured before and after atorvastatin as well as before and after fenofibrate . Ghrelin ( 462±84 pg/ml before vs. 464±102 pg/ml after atorvastatin , n.s . ; 454±85 pg/ml before vs. 529±266 pg/ml after fenofibrate , n.s . ) , resistin ( 24.4±7.4 pg/ml before vs. 23.7±9.1 pg/ml after atorvastatin , n.s . ; 23.4±8.2 pg/ml before vs. 19.9±5.5 pg/ml after fenofibrate , n.s . ) , adiponectin ( 10.89±5.33 pg/ml before vs. 12.41±5.75 pg/ml after atorvastatin , n.s . ; 12.58±9.87 pg/ml before vs. 10.27±5.23 pg/ml after fenofibrate , n.s . ) and insulin levels did not change significantly during lipid-lowering therapy . In patients with type 2 diabetes and mixed hyperlipoproteinaemia , short-term atorvastatin as well as fenofibrate therapy had no significant effects on adiponectin , ghrelin or resistin levels
CONCLUSIONS The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect  compared with statin monotherapy .
AIMS Statins are known to influence the status of adipokines , which play a key role in the pathophysiology of cardiometabolic diseases .
As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear , the aim of the present study was to investigate this through a meta- analysis of controlled trials .